Printer Friendly

CYTOGEN ANNOUNCES 1992 ANNUAL MEETING HIGHLIGHTS

 CYTOGEN ANNOUNCES 1992 ANNUAL MEETING HIGHLIGHTS
 PRINCETON, N.J., May 19 /PRNewswire/ -- Cytogen Corporation


(NASDAQ: CYTO) held its 1992 Annual Stockholders Meeting in Princeton today, where the company's management discussed the highlights of an excellent year of growth and development.
 George W. Ebright, chairman and chief executive officer, and President, Thomas J. McKearn, M.D., Ph.D., made presentations regarding Cytogen's progress towards the first product approvals for the OncoScint cancer imaging agents and stated that the company is well positioned for the future with financial resources, therapy products, and next generation technology. The presentation included:
 -- Cytorad units offering raised over $40 million and will pay Cytogen substantial contract revenue over the next few years.
 -- OncoScint colorectal launched in six European markets: Germany, Luxembourg, Netherlands, Denmark, Italy, and Spain.
 -- First product-related source of revenue -- from sale of product to customers, by EuroCetus.
 -- Competition is at minimal levels; no one has developed products for our markets with lower doses and higher sensitivity.
 -- Next generation targeting delivery system, the MRU, already in the clinic.
 -- OncoScint prostate, the imaging agent for prostate cancer, moving into Phase III clinical studies in a few months.
 -- OncoRad prostate, the prostate cancer therapy agent, will begin clinical trials shortly.
 -- OncoRad ovarian, the therapy agent for ovarian cancer, continues to experience success in Phase I trials.
 Cytogen is a biopharmaceutical company engaged in the development of proprietary systems utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances in human health care applications. Cytogen uses its patented and proprietary antibody "linker" technology to develop specific cancer diagnostic imaging and cancer therapeutic products, as well as certain other products.
 Cytorad, a newly formed company, will receive all the proceeds of the offering and engage in the research and development of monoclonal antibody-based delivery systems for the diagnosis and treatment of prostate and bladder cancers utilizing Cytogen Corporation's proprietary and patented technology.
 /delval/
 -0- 5/19/92
 /CONTACT: Laura M. Hahn or Colleen P. Cottrell of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation ST: New Jersey IN: MTC SU:


JS -- PH005 -- 1817 05/19/92 12:16 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:349
Previous Article:'CORVETTE BULLDOZER' TO BE USED IN GROUNDBREAKING FOR NATIONAL CORVETTE MUSEUM JUNE 5
Next Article:ROBERTS PHARMACEUTICAL REPORTS RECORD LEVEL FIRST QUARTER SALES
Topics:


Related Articles
FDA ADVISORY COMMITTEE TO REVIEW CANCER IMAGING PRODUCT
CYTOGEN ANNOUNCES FDA REVIEW UPDATE
CYTOGEN ANNOUNCES DIVIDEND PAYMENT ON CONVERTIBLE EXCHANGEABLE PREFERRED STOCK
CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT
CYTOGEN CORPORATION ANNOUNCES DIVIDEND ON ITS PREFERRED STOCK AND PROBABLE REDEMPTION OF ITS PREFERRED STOCK
CYTOGEN CORPORATION ANNOUNCES THIRD QUARTER RESULTS
CYTOGEN CORPORATION ANNOUNCES FOURTH QUARTER RESULTS
CYTOGEN AND CELLCOR ANNOUNCE SPECIAL MEETINGS TO APPROVE MERGER
CYTOGEN STOCKHOLDERS APPROVE MERGER WITH CELLCOR
CYTOGEN Announces Issuance of PSMA Patent

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters